20 September, 2017
As discussed in Biotechnology: Where the Promise of Life Meets the Reality of Markets, our preference is for a core and satellite approach as opposed to taking concentrated positions in a handful of stocks.
In this case, $IBB and $XPH form our core and will receive 60% of our healthcare allocation. With the remaining 40% allocated to the satellites comprised of the following stocks:
- Regeneron Pharmaceuticals $REGN – highest conviction idea
- Bristol-Myers Squibb $BMY
- Biogen Inc $BIIB
- Perrigo Co $PRGO
- Alexion Pharmaceuticals $ALXN
- Cerner Corporation $CERN – lowest conviction idea
Trade Ideas should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.